Clinical trial
FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic…
NCT00077233 · Alliance for Clinical Trials in Oncology, Other · Terminated
Key facts
| NCT number | NCT00077233 |
|---|---|
| Title | FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum |
| Official title | A Phase II Trial Of Irinotecan /5-FU/ Leucovorin Or Oxaliplatin /5-FU / Leucovorin With And Without Cetuximab (C225) For Patients With Untreated Metastatic Adenocarcinoma Of The Colon or Rectum |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH Bristol-Myers Squibb Industry Eli Lilly and Company |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | cetuximab, 5-FU, irinotecan, leucovorin, oxaliplatin |
| Enrollment | 238 |
| Start date | Dec 1, 2003 |
| Primary completion | Dec 1, 2006 |
| Completion | Jun 1, 2010 |
| First posted | Feb 11, 2004 |
| Last update posted | May 16, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: